H3 Biomedicine is a biopharmaceutical company that specializes in the discovery and development of precision oncology treatments. Established as a subsidiary of Eisai’s U.S. pharmaceutical operation, Eisai Inc. provides research funding and access to its capabilities and resources. H3 Biomedicine combines long-term vision with operational independence using modern synthetic chemistry, chemical biology, and human genetics to bring next generation cancer treatments to patients.